Bone Therapeutics announced it has appointed Anne Leselbaum, MD as Chief Medical Officer (CMO), effective 23 August 2021. As CMO, Dr. Leselbaum will take responsibility for the leadership of all clinical development and medical affairs strategies and activities across the entire the company’s pipeline and will oversee the regulatory interactions as the company’s clinical assets JTA-004 and ALLOB are moving through clinical development towards commercialization. Dr. Leselbaum was most recently Vice President Clinical Development at Aelix Therapeutics.